{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T23:38:25Z","timestamp":1769557105024,"version":"3.49.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,4]]},"DOI":"10.7759\/cureus.29923","type":"journal-article","created":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T02:35:34Z","timestamp":1664937334000},"source":"Crossref","is-referenced-by-count":8,"title":["A Correlation Between the Pathogenic Processes of Fibromyalgia and Irritable Bowel Syndrome in the Middle-Aged Population: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Carla","family":"Valencia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hameeda","family":"Fatima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ijeoma","family":"Nwankwo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahvish","family":"Anam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shrinkhala","family":"Maharjan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zainab","family":"Amjad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdelrahman","family":"Abaza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Advait M","family":"Vasavada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akhil","family":"Sadhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Safeera","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00338.2016","article-title":"Irritable bowel syndrome: a gut microbiota-related disorder?","volume":"312","author":"Bhattarai Y","year":"2017","unstructured":"Bhattarai Y, Muniz Pedrogo DA, Kashyap PC. Irritable bowel syndrome: a gut microbiota-related disorder?. Am J Physiol Gastrointest Liver Physiol. 2017, 312:G52-62. 10.1152\/ajpgi.00338.2016","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.06.051","article-title":"Vasoactive intestinal polypeptide and mast cells regulate increased passage of colonic bacteria in patients with irritable bowel syndrome","volume":"153","author":"Bednarska O","year":"2017","unstructured":"Bednarska O, Walter SA, Casado-Bedmar M, et al.. Vasoactive intestinal polypeptide and mast cells regulate increased passage of colonic bacteria in patients with irritable bowel syndrome. Gastroenterology. 2017, 153:948-960.e3. 10.1053\/j.gastro.2017.06.051","journal-title":"Gastroenterology"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13848","article-title":"Increased expression of nerve growth factor correlates with visceral hypersensitivity and impaired gut barrier function in diarrhoea-predominant irritable bowel syndrome: a preliminary explorative study","volume":"45","author":"Xu XJ","year":"2017","unstructured":"Xu XJ, Zhang YL, Liu L, Pan L, Yao SK. Increased expression of nerve growth factor correlates with visceral hypersensitivity and impaired gut barrier function in diarrhoea-predominant irritable bowel syndrome: a preliminary explorative study. Aliment Pharmacol Ther. 2017, 45:100-14. 10.1111\/apt.13848","journal-title":"Aliment Pharmacol Ther"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000006657","article-title":"Risk for irritable bowel syndrome in fibromyalgia patients: a national database study","volume":"96","author":"Yang TY","year":"2017","unstructured":"Yang TY, Chen CS, Lin CL, Lin WM, Kuo CN, Kao CH. Risk for irritable bowel syndrome in fibromyalgia patients: a national database study. Medicine (Baltimore). 2017, 96:e6657. 10.1097\/MD.0000000000006657","journal-title":"Medicine (Baltimore)"},{"key":"ref5","article-title":"Inflammatory markers in the diagnosis of fibromyalgia","volume":"23","author":"Khamisy-Farah R","year":"2021","unstructured":"Khamisy-Farah R, Fund E, Raibman-Spector S, et al.. Inflammatory markers in the diagnosis of fibromyalgia. Isr Med Assoc J. 2021, 23:801-4.","journal-title":"Isr Med Assoc J"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21041186","article-title":"T cell subpopulations in the physiopathology of fibromyalgia: evidence and perspectives","volume":"21","author":"Banfi G","year":"2020","unstructured":"Banfi G, Diani M, Pigatto PD, Reali E. T cell subpopulations in the physiopathology of fibromyalgia: evidence and perspectives. Int J Mol Sci. 2020, 21:10.3390\/ijms21041186","journal-title":"Int J Mol Sci"},{"key":"ref7","article-title":"New insights into the genetics of fibromyalgia","volume":"32","author":"Park DJ","year":"2017","unstructured":"Park DJ, Lee SS. New insights into the genetics of fibromyalgia. Korean J Intern Med. 2017, 32:984-95.","journal-title":"Korean J Intern Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1177\/1756284820977402","article-title":"A systematic review of the association between fibromyalgia and functional gastrointestinal disorders","volume":"13","author":"Erdrich S","year":"2020","unstructured":"Erdrich S, Hawrelak JA, Myers SP, Harnett JE. A systematic review of the association between fibromyalgia and functional gastrointestinal disorders. Therap Adv Gastroenterol. 2020, 13:1756284820977402. 10.1177\/1756284820977402","journal-title":"Therap Adv Gastroenterol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, Moher D, Bossuyt PM, et al.. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021, 372:n160. 10.1136\/bmj.n160","journal-title":"BMJ"},{"key":"ref10","unstructured":"MeSH. (1960). Accessed. May 19, 2022: https:\/\/www.ncbi.nlm.nih.gov\/mesh\/."},{"key":"ref11","unstructured":"PubMed Central. (2000). Accessed. May, 2022: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/."},{"key":"ref12","unstructured":"Cochrane Library. (2000). Accessed. May 20, 2022: https:\/\/www.cochranelibrary.com\/."},{"key":"ref13","unstructured":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. (2021). Accessed. 2022: https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp."},{"key":"ref14","unstructured":"Cognibrain. (2019). Accessed. 2022: https:\/\/www.cognibrain.com\/sanra-tool-for-assessing-narrative-review-articles\/."},{"key":"ref15","unstructured":"AMSTAR. (2021). Accessed. 2022: https:\/\/amstar.ca\/Amstar_Checklist.php."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/9624702","article-title":"Increased expression of toll-like receptors 4, 5, and 9 in small bowel mucosa from patients with irritable bowel syndrome","volume":"2017","author":"Dlugosz A","year":"2017","unstructured":"Dlugosz A, Zakikhany K, Acevedo N, D'Amato M, Lindberg G. Increased expression of toll-like receptors 4, 5, and 9 in small bowel mucosa from patients with irritable bowel syndrome. Biomed Res Int. 2017, 2017:9624702. 10.1155\/2017\/9624702","journal-title":"Biomed Res Int"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.4103\/IJPM.IJPM_544_16","article-title":"Levels of interleukins 2, 6, 8, and 10 in patients with irritable bowel syndrome","volume":"60","author":"Patel SR","year":"2017","unstructured":"Patel SR, Singh A, Misra V, Misra SP, Dwivedi M, Trivedi P. Levels of interleukins 2, 6, 8, and 10 in patients with irritable bowel syndrome. Indian J Pathol Microbiol. 2017, 60:385-9. 10.4103\/IJPM.IJPM_544_16","journal-title":"Indian J Pathol Microbiol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.5152\/tjg.2018.17491","article-title":"Does the number of mucosal immune cells differ in irritable bowel syndrome and its subtypes?","volume":"29","author":"\u0130liaz R","year":"2018","unstructured":"\u0130liaz R, Aky\u00fcz F, Ye\u011fen G, et al.. Does the number of mucosal immune cells differ in irritable bowel syndrome and its subtypes?. Turk J Gastroenterol. 2018, 29:384-91. 10.5152\/tjg.2018.17491","journal-title":"Turk J Gastroenterol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i1.46","article-title":"Increased intestinal mucosal leptin levels in patients with diarrhea-predominant irritable bowel syndrome","volume":"24","author":"Liu DR","year":"2018","unstructured":"Liu DR, Xu XJ, Yao SK. Increased intestinal mucosal leptin levels in patients with diarrhea-predominant irritable bowel syndrome. World J Gastroenterol. 2018, 24:46-57. 10.3748\/wjg.v24.i1.46","journal-title":"World J Gastroenterol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.4274\/balkanmedj.galenos.2019.2019.6.47","article-title":"Elevated serum levels of monocyte chemotactic protein-1\/chemokine C-C motif ligand 2 are linked to disease severity in patients with fibromyalgia syndrome","volume":"36","author":"Zhao YC","year":"2019","unstructured":"Zhao YC, Hu T, Chen Y, Du KT. Elevated serum levels of monocyte chemotactic protein-1\/chemokine C-C motif ligand 2 are linked to disease severity in patients with fibromyalgia syndrome. Balkan Med J. 2019, 36:331-6. 10.4274\/balkanmedj.galenos.2019.2019.6.47","journal-title":"Balkan Med J"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.14130","article-title":"Altered interaction between enteric glial cells and mast cells in the colon of women with irritable bowel syndrome","volume":"33","author":"Meira de-Faria F","year":"2021","unstructured":"Meira de-Faria F, Casado-Bedmar M, M\u00e5rten Lindqvist C, Jones MP, Walter SA, Keita \u00c5V. Altered interaction between enteric glial cells and mast cells in the colon of women with irritable bowel syndrome. Neurogastroenterol Motil. 2021, 33:e14130. 10.1111\/nmo.14130","journal-title":"Neurogastroenterol Motil"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0252930","article-title":"Disruption of the pro-inflammatory, anti-inflammatory cytokines and tight junction proteins expression, associated with changes of the composition of the gut microbiota in patients with irritable bowel syndrome","volume":"16","author":"Ivashkin V","year":"2021","unstructured":"Ivashkin V, Poluektov Y, Kogan E, et al.. Disruption of the pro-inflammatory, anti-inflammatory cytokines and tight junction proteins expression, associated with changes of the composition of the gut microbiota in patients with irritable bowel syndrome. PLoS One. 2021, 16:e0252930. 10.1371\/journal.pone.0252930","journal-title":"PLoS One"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.22034\/IJI.2021.90539.2013","article-title":"Evaluation of the relationship between proinflammatory cytokine levels and clinical findings of fibromyalgia syndrome","volume":"18","author":"Ellergezen P","year":"2021","unstructured":"Ellergezen P, Alp A, \u00c7avun S. Evaluation of the relationship between proinflammatory cytokine levels and clinical findings of fibromyalgia syndrome. Iran J Immunol. 2021, 18:338-45. 10.22034\/IJI.2021.90539.2013","journal-title":"Iran J Immunol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2020.11.035","article-title":"Fatigue in irritable bowel syndrome is associated with plasma levels of TNF-\u03b1 and mesocorticolimbic connectivity","volume":"92","author":"Norlin AK","year":"2021","unstructured":"Norlin AK, Walter S, Icenhour A, et al.. Fatigue in irritable bowel syndrome is associated with plasma levels of TNF-\u03b1 and mesocorticolimbic connectivity. Brain Behav Immun. 2021, 92:211-22. 10.1016\/j.bbi.2020.11.035","journal-title":"Brain Behav Immun"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.20452\/pamw.4364","article-title":"Evaluation of serotonin and dopamine secretion and metabolism in patients with irritable bowel syndrome","volume":"128","author":"Chojnacki C","year":"2018","unstructured":"Chojnacki C, B\u0142o\u0144ska A, Kaczka A, Chojnacki J, St\u0119pie\u0144 A, G\u0105siorowska A. Evaluation of serotonin and dopamine secretion and metabolism in patients with irritable bowel syndrome. Pol Arch Intern Med. 2018, 128:711-3. 10.20452\/pamw.4364","journal-title":"Pol Arch Intern Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.15403\/jgld-229","article-title":"Mast cells in irritable bowel syndrome: a systematic review","volume":"28","author":"Krammer L","year":"2019","unstructured":"Krammer L, Sowa AS, Lorentz A. Mast cells in irritable bowel syndrome: a systematic review. J Gastrointestin Liver Dis. 2019, 28:463-72. 10.15403\/jgld-229","journal-title":"J Gastrointestin Liver Dis"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab146","article-title":"Is fibromyalgia associated with a unique cytokine profile? A systematic review and meta-analysis","volume":"60","author":"O'Mahony LF","year":"2021","unstructured":"O'Mahony LF, Srivastava A, Mehta P, Ciurtin C. Is fibromyalgia associated with a unique cytokine profile? A systematic review and meta-analysis. Rheumatology (Oxford). 2021, 60:2602-14. 10.1093\/rheumatology\/keab146","journal-title":"Rheumatology (Oxford)"},{"key":"ref28","unstructured":"PRISMA. (2021). Accessed. 2022: https:\/\/prisma-statement.org\/PRISMAStatement\/PRISMAStatement."},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/gz4i3i","article-title":"One year in review 2021: fibromyalgia","volume":"39 Suppl 130","author":"Alciati A","year":"2021","unstructured":"Alciati A, Nucera V, Masala IF, et al.. One year in review 2021: fibromyalgia. Clin Exp Rheumatol. 2021, 39 Suppl 130:3-12. 10.55563\/clinexprheumatol\/gz4i3i","journal-title":"Clin Exp Rheumatol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.20524\/aog.2018.0229","article-title":"Current insights into the innate immune system dysfunction in irritable bowel syndrome","volume":"31","author":"Lazaridis N","year":"2018","unstructured":"Lazaridis N, Germanidis G. Current insights into the innate immune system dysfunction in irritable bowel syndrome. Ann Gastroenterol. 2018, 31:171-87. 10.20524\/aog.2018.0229","journal-title":"Ann Gastroenterol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3390\/ijms221910235","article-title":"Enteric microbiota-mediated serotonergic signaling in pathogenesis of irritable bowel syndrome","volume":"22","author":"Mishima Y","year":"2021","unstructured":"Mishima Y, Ishihara S. Enteric microbiota-mediated serotonergic signaling in pathogenesis of irritable bowel syndrome. Int J Mol Sci. 2021, 22:10.3390\/ijms221910235","journal-title":"Int J Mol Sci"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/107504-a-correlation-between-the-pathogenic-processes-of-fibromyalgia-and-irritable-bowel-syndrome-in-the-middle-aged-population-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:40:57Z","timestamp":1707507657000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/107504-a-correlation-between-the-pathogenic-processes-of-fibromyalgia-and-irritable-bowel-syndrome-in-the-middle-aged-population-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,4]]},"references-count":31,"URL":"https:\/\/doi.org\/10.7759\/cureus.29923","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,4]]}}}